Trial Profile
A study evaluating paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin in patients with compensated liver cirrhosis with hepatitis B virus + hepatitis C virus coinfection: a national cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis B; Hepatitis C
- Focus Therapeutic Use
- 08 Jul 2017 New trial record